Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: A systematic review and meta-analysis of randomised controlled trials.

Matthew Meng Yang Lee Toru Kondo Ross T Campbell Mark Colquhoun Petrie Naveed SattarScott D SolomonMuthiah Vaduganathan Pardeep S Jhund John Joseph Valentine McMurray

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

ACE inhibitors and ARBs may be continued in non-severe COVID-19 infection, where indicated. Conversely, initiation of RAS blockers may be harmful in critically ill patients. PROSPERO registration number: CRD42023408926.

Keyphrases

angiotensin converting enzyme
angiotensin ii
coronavirus disease
sars cov
early onset
wild type
respiratory syndrome coronavirus
drug induced